期刊文献+

Fast reaction and long duration--application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation:A case report

下载PDF
导出
摘要 The prognosis of patients with advanced melanoma is poor.The five-year recurrence rate is approximately 70%,whereas the overall survival rate is only 4%-10%.We report the case of a 61-year-old male patient with metastatic melanoma(B-Raft).The tumor load of the patient was significantly reduced after the application of dabrafenib plus trametinib(“DtT”)and radiotherapy.Further,it is suggested that medical staff should conduct a comprehensive analysis of the patient’s condition when dealing with adverse events(AEs)associated with such malignant tumors to provide evidence for adopting the appropriate targeted treatment or radiotherapy and nursing mode and achieve the best treatment effect.
出处 《Chinese Journal Of Plastic and Reconstructive Surgery》 2021年第4期193-196,共4页 中国整形与重建外科(英文)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部